On September 8, 2026 Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, reported that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human cancer and the company’s upcoming Phase 2 readout in endometrial cancer. To register, click here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will provide an overview of the PAM pathway, a critical signaling network that regulates cell growth, survival, and metabolism and one of the most frequently altered oncogenic signaling pathways in human cancer. Management will compare single-node inhibition with PIKTOR, Faeth’s investigational multi-node inhibitor that uses a vertical pathway-blockade strategy combining the PI3K inhibitor serabelisib and the mTOR inhibitor sapanisertib. During the call, management will discuss recent translational work that led to the dose and schedule of PIKTOR currently being evaluated in its Phase 2 trial as well as clinical data from a prior Phase 1b trial. Management will also highlight the unmet need for novel therapies in endometrial cancer, where approximately 80% of tumors harbor a PAM pathway alteration, and treatment options following checkpoint inhibitor therapy remain limited. Topline data from the company’s Phase 2 trial is anticipated by year-end.
A live question and answer session will follow the formal presentations.
About Marcus Goncalves, MD, PhD
Marcus Goncalves, MD, PhD serves as the Director of the Holman Division of Endocrinology, Diabetes, and Metabolism and an Associate Professor of Endocrinology at NYU Langone Health, where he leads research into how diet, insulin, and systemic metabolism regulate cancer growth. As a practicing endocrinologist, he has helped develop therapeutic and dietary strategies to modulate glucose and insulin levels in patients with cancer. His work in the Cantley Lab at Weill Cornell Medicine on the relationship between fructose metabolism, insulin signaling, and tumor progression was published in Nature and Science and directly informed Faeth’s founding thesis. Dr. Goncalves holds an M.D. and Ph.D. from the University of Pennsylvania.
About PIKTOR
PIKTOR is an investigational, proprietary, all-oral combination of serabelisib, a selective PI3K-alpha inhibitor, and sapanisertib, an mTORC1/mTORC2 inhibitor, designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway. According to published literature, this pathway is dysregulated in up to 50% of all solid tumors, making it one of the most prevalent therapeutic targets in oncology. PIKTOR is being evaluated in a Phase 2 trial in second-line advanced endometrial cancer (Study FTH-PIK-201), with topline data anticipated by year-end 2026. PIKTOR is also being evaluated in a Phase 1b/2 trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101), in which the first patient was dosed in April and interim data is anticipated in 2027.
(Press release, Faeth Therapeutics, SEP 8, 2026, View Source [SID1234670635])